View Report
March 23, 2026
Measured Result 1.09 mg 109.00% of label claim
Axiolabs
Axiolabs
Latest Laboratory Result 1.09 mg March 23, 2026 · 109% of label claim View
Arimiplex 1 mg
Product Information Compound Details
Active Substance Anastrozole Nonsteroidal Aromatase Inhibitor
1 mg/tabletStrength 1 mg/tablet
Package 50 or 100 Tablets
Form Oral Tablets
Drug Class Aromatase Inhibitor
Inhibitor Type Nonsteroidal
Manufacturer Axiolabs
$100.00
Amount :
50 tabs
100 tabs
Shipping :
International
U.S. Domestic
Product Overview
Arimiplex 1 mg by Axiolabs
Arimiplex 1 mg is an oral tablet containing Anastrozole, manufactured by Axiolabs and supplied as 1 mg per tablet in 50 or 100 tablet packages.
Anastrozole Oral
Arimiplex 1 mg contains anastrozole, a potent and selective nonsteroidal aromatase inhibitor. Anastrozole works by binding reversibly to the aromatase enzyme (CYP19), blocking the conversion of androgens such as testosterone and androstenedione to estrogens including estradiol and estrone. This mechanism reduces circulating estrogen levels, which is the basis for its clinical use in hormone receptor-positive breast cancer.
Anastrozole is FDA-approved under the brand name Arimidex for three indications: adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, and treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. The standard dose is 1 mg once daily.
In non-medical bodybuilding contexts, anastrozole is referenced off-label for managing estrogenic side effects during anabolic steroid cycles, including water retention and gynecomastia risk. However, anastrozole is not approved for this use, and the FDA label does not support its application in men or for performance enhancement. Aromatase inhibitors are prohibited in sport by WADA and are included in doping control analyses.
Research Properties of Arimiplex 1 mg
- Potent nonsteroidal aromatase inhibitor (CYP19)
- FDA-approved for hormone receptor-positive breast cancer in postmenopausal women
- Reduces estrogen synthesis by blocking androgen-to-estrogen conversion
- Standard clinical dose of 1 mg once daily
- 1 mg per tablet for research applications
Product Profile
Anastrozole Profile
Anastrozole is a third-generation nonsteroidal aromatase inhibitor with established efficacy in hormone receptor-positive breast cancer. Its research profile includes extensive clinical trial data spanning over two decades.
Nonsteroidal Aromatase Inhibitor
Anastrozole belongs to the class of aromatase inhibitors, which are classified as steroidal (type I, irreversible) or nonsteroidal (type II, reversible). Anastrozole is a nonsteroidal, reversible inhibitor that binds competitively to the aromatase enzyme's substrate-binding site. Aromatase is responsible for the final step in estrogen biosynthesis, converting androgens to estrogens in peripheral tissues including adipose tissue, muscle, and breast tissue.
The pharmacokinetic profile of anastrozole includes a mean elimination half-life of approximately 50 hours. Hepatic metabolism accounts for approximately 85% of anastrozole elimination, with renal elimination accounting for approximately 10% of total clearance. Steady-state plasma concentrations are achieved within 7 days of daily dosing, with no age-related effects observed over the range of less than 50 to greater than 80 years.
Clinical trial data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial established anastrozole's efficacy in adjuvant breast cancer treatment. The 10-year analysis demonstrated disease-free survival of 89.4% versus 87.4% for tamoxifen. For patients with low Oncotype Recurrence Scores (0-17), a recent comparative study found no statistically significant difference in 10-year overall survival or local recurrence between anastrozole and tamoxifen.
Defining Characteristic
Reversible Nonsteroidal Inhibition
Anastrozole's defining pharmacological characteristic is its reversible, competitive inhibition of aromatase, distinguishing it from irreversible steroidal inhibitors like exemestane.
Arimiplex 1 mg vs Other Axiolabs Preparations
Axiolabs offers several ancillary and hormone-related products referenced in bodybuilding research. Exeplex (exemestane) is a steroidal aromatase inhibitor that irreversibly binds aromatase. Letroplex (letrozole) is a nonsteroidal aromatase inhibitor with greater potency than anastrozole. Tamoxiplex (tamoxifen) is a selective estrogen receptor modulator that blocks estrogen action rather than inhibiting its synthesis. Arimiplex provides reversible aromatase inhibition with a well-characterized clinical profile.
Laboratory Testing
Arimiplex 1 mg Lab Reports
Published laboratory reports for Arimiplex 1 mg by Axiolabs are shown below with the test date, measured content and percentage of the product's 1 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
Arimiplex 1 mg Dosage & Usage
The information below is provided for educational reference only. Anastrozole is a prescription medicine; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
Typical Dosage Ranges
In medically supervised breast cancer treatment, the standard anastrozole dose is 1 mg once daily, continued until tumor progression for advanced disease or for up to 5 years for adjuvant therapy. In non-medical bodybuilding contexts, anastrozole is referenced at lower doses for managing estrogenic side effects, though this use is not supported by the FDA label. Community protocols vary widely, and no standardized non-clinical dosing has been established.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Medical (breast cancer) | 1 mg | Once daily |
| Adjuvant therapy duration | Up to 5 years | Per clinical protocol |
| Non-medical (not approved) | Varies; not standardized | Not established |
Important Safety Considerations
Anastrozole is associated with significant adverse effects that require monitoring. The FDA label warns of ischemic cardiovascular events in women with pre-existing ischemic heart disease, decreased bone mineral density, and increased serum cholesterol. In the ATAC trial, the cumulative incidence of first fractures was 15% in the anastrozole group compared to 11% in the tamoxifen group. Bone mineral density monitoring is recommended during treatment.
Contraindications and Interactions
Anastrozole is contraindicated in patients with hypersensitivity to the drug or excipients. It should not be used in combination with tamoxifen, as no additional benefit was seen over tamoxifen monotherapy. Estrogen-containing products may diminish anastrozole activity and should be avoided. Anastrozole can cause fetal harm and is contraindicated in pregnancy.
Important
Individual Response Varies
The information above is for educational reference and does not constitute medical advice. Anastrozole is a prescription medicine with significant adverse effects and drug interactions.
Safety & Information
Anastrozole Safety Information
Anastrozole is a prescription aromatase inhibitor with significant adverse effects. Medical use requires appropriate diagnosis, clinical supervision, and monitoring.
Important Safety Information
Anastrozole therapy is associated with several important risks. In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with anastrozole compared to tamoxifen (17% vs 10%). Decreases in bone mineral density may occur, and bone mineral density monitoring is recommended. Increases in total cholesterol may occur, warranting cholesterol monitoring. Anastrozole can cause fetal harm and is contraindicated in pregnancy.
Important
Non-Medical Use
Non-medical use of anastrozole falls outside approved indications. Anastrozole is not approved for managing estrogenic side effects in men or for performance enhancement. Aromatase inhibitors are prohibited in sport and subject to doping control.
Potential Adverse Effects
Common adverse reactions in clinical trials include asthenia (16%), pain (14%), back pain (12%), headache (9%), hot flushes (26%), nausea (19%), and peripheral edema (10%). The ATAC trial at 10-year follow-up showed that the cumulative incidence of all first fractures was higher in the anastrozole group (15%) compared to the tamoxifen group (11%). Endometrial cancer was higher in the tamoxifen group (0.8%) compared to the anastrozole group (0.2%).
Conditions Requiring Medical Evaluation
Anastrozole should be used with caution in patients with pre-existing ischemic heart disease due to increased cardiovascular event risk. Bone mineral density should be monitored, particularly in patients with osteoporosis risk factors. Cholesterol levels should be monitored as anastrozole may increase total cholesterol. Anastrozole is contraindicated in pregnancy and should not be used during breastfeeding.
Monitoring Considerations
During anastrozole therapy, monitoring may include bone mineral density assessment, lipid panel, and cardiovascular risk evaluation. In clinical trials, patients receiving anastrozole had a mean decrease in lumbar spine and total hip bone mineral density compared to baseline, while tamoxifen patients had a mean increase. Following treatment cessation, anastrozole-related bone loss did not continue into the off-treatment follow-up period.
Product Care
Storage & Handling
Store tablets in a closed container at room temperature, away from heat, moisture, and direct light. Keep out of reach of children. Do not use if the packaging is damaged or if tablets appear discolored.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Arimiplex 1 mg by Axiolabs is supplied through the official distribution chain and shipped with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Axiolabs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is available
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Arimiplex 1 mg product, use the security code on the packaging and cross-check it on the official Axiolabs site. A laboratory report dated March 23, 2026 measured the content at 1.09 mg per tablet, equivalent to 109% of the 1 mg label claim. Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Arimiplex 1 mg Storage
Proper storage conditions help preserve tablet integrity and maintain product stability throughout shelf life.
Recommended Conditions
Store tablets in a closed container at controlled room temperature (15–25°C), away from excessive heat, moisture, and direct light. Keep the product in its original packaging until use.
Do not use if the packaging is damaged or if tablets appear discolored or degraded. Keep out of reach of children.
Quick Reference
Do & Don't
- Do store at 15–25°C
- Do keep in original packaging
- Do protect from moisture and light
- Don't expose to excessive heat
- Don't use if tablets appear discolored
- Don't store in bathroom or humid areas
Frequently Asked Questions
Arimiplex 1 mg FAQ
Answers to common questions about Arimiplex 1 mg, anastrozole research, and product details.
What is Arimiplex 1 mg used for?
Arimiplex 1 mg contains anastrozole, an aromatase inhibitor. In medical practice, it is FDA-approved for hormone receptor-positive breast cancer in postmenopausal women. In non-medical bodybuilding contexts, it is referenced off-label for managing estrogenic side effects, though this use is not approved.
How often should Arimiplex 1 mg be taken?
The FDA-approved dose is 1 mg once daily. In adjuvant breast cancer treatment, anastrozole is typically continued for up to 5 years. Non-medical dosing is not standardized and falls outside approved indications.
Does Arimiplex 1 mg require PCT?
Anastrozole is not an anabolic steroid and does not suppress testosterone production in the same way. Post-cycle therapy designed for steroid cycles is not applicable. Its mechanism involves aromatase inhibition and estrogen suppression, not hormonal suppression of the HPTA.
What does anastrozole do?
Anastrozole binds reversibly to the aromatase enzyme (CYP19), blocking the conversion of androgens such as testosterone to estrogens including estradiol. This reduces circulating estrogen levels and is the basis for its use in hormone receptor-positive breast cancer.
How long does anastrozole take to work?
Anastrozole has a mean elimination half-life of approximately 50 hours, and steady-state plasma concentrations are achieved within 7 days of daily dosing. Estrogen suppression occurs rapidly after initiating therapy.
Is anastrozole the best aromatase inhibitor?
No single aromatase inhibitor is universally superior. Anastrozole, letrozole, and exemestane are all approved for breast cancer treatment. A recent comparative study found no difference in 10-year outcomes between anastrozole and tamoxifen for low-risk patients.
What is the difference between Arimiplex and Exeplex?
Exeplex contains exemestane, a steroidal aromatase inhibitor that irreversibly binds aromatase. Arimiplex contains anastrozole, a nonsteroidal inhibitor that binds reversibly. Both reduce estrogen synthesis but through different mechanisms.
What is the difference between Arimiplex and Tamoxiplex?
Tamoxiplex contains tamoxifen, a selective estrogen receptor modulator that blocks estrogen action at the receptor level. Arimiplex (anastrozole) inhibits estrogen synthesis by blocking aromatase. These are fundamentally different mechanisms of estrogen management.
Is 1 mg of anastrozole a lot?
1 mg is the FDA-approved daily dose for breast cancer treatment. The laboratory report for this Arimiplex product measured 1.09 mg per tablet, which is 109% of the 1 mg label claim. This represents a slight overage consistent with pharmaceutical manufacturing standards.
What strength is Arimiplex 1 mg?
Arimiplex 1 mg by Axiolabs contains 1 mg of anastrozole per tablet. It is supplied in packages of 50 or 100 tablets. A laboratory report dated March 23, 2026 measured the content at 1.09 mg, equivalent to 109% of the label claim.
Is Arimiplex 1 mg lab tested?
Yes. A published laboratory report dated March 23, 2026 measured Arimiplex 1 mg at 1.09 mg per tablet, equivalent to 109% of its 1 mg label claim. The complete report can be viewed in the Lab Reports tab.
What are the risks of anastrozole in men?
Anastrozole is not approved for use in men for estrogen management. In clinical studies of pubertal gynecomastia, anastrozole was ineffective. Potential risks include bone mineral density loss, cardiovascular events, and cholesterol elevation. Aromatase inhibitors are prohibited in sport.
Related Offers
Axiolabs
Product Information
Compound Details
Active Substance
Clomiphene Citrate
Selective Estrogen Receptor Modulator (SERM)
50 mg/tablet
Strength
50 mg/tablet
Package
50 or 100 Tablets
Form
Oral Tablets
Drug Class
SERM
Selective Estrogen Receptor Modulator
Receptor Target
Estrogen Receptor
Manufacturer
Axiolabs
Shipped USA Domestic
Axiolabs
Product Information
Compound Details
Active Substance
Exemestane
Irreversible Steroidal Aromatase Inhibitor
25 mg/tablet
Strength
25 mg/tablet
Package
50 or 100 Tablets
Form
Oral Tablets
Drug Class
Steroidal Aromatase Inhibitor
Inhibition Type
Irreversible
Manufacturer
Axiolabs
$88.00
Axiolabs
Product Information
Compound Details
Active Substance
Tamoxifen Citrate
Selective Estrogen Receptor Modulator (SERM)
20 mg
Strength
20 mg/tablet
Package
50 or 100 Tablets
1,000 mg or 2,000 mg Total Labeled Content
Form
Oral Tablets
Drug Class
SERM
Selective Estrogen Receptor Modulator
Estimated Half-Life
Approximately 5–7 Days
Manufacturer
Axiolabs
Shipped USA Domestic
Axiolabs
Product Information Compound Details
Active Substance Letrozole Nonsteroidal Competitive Aromatase Inhibitor
2.5 mg/tabletStrength 2.5 mg/tablet
Package 50 or 100 Tablets
Form Oral Tablets
Drug Class Aromatase Inhibitor
Inhibition Type Reversible / Competitive
Manufacturer Axiolabs
$66.00